NCT05256641 - Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2026

Conditions

Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed LymphomaSecondary Central Nervous System Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

Trial Locations (3)

NOT_YET_RECRUITING

University of Oklahoma, Oklahoma City

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento